Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 169

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 169
---
, principally offset by increases in Qelbree due to higher sales and ONAPGO, which was launched in the second quarter of 2025. 

Research and Development Expenses

Research and Development (R&D) expenses were $29.4 million and $29.0 million for the three months ended September 30, 2025 and 2024, respectively. R&D expenses were $78.4 million and $80.1 million for the nine months ended September 30, 2025 and 2024, respectively. The decrease in the year to date period was primarily due to decreased clinical program costs on SPN-820, partially offset by the increase in clinical program costs on SPN-817 and the Company's share of R&D expenses from the collaboration arrangement with Biogen. The Company acquired a collaboration agreement with Biogen as part of the acquisition of Sage in July 2025. 

Selling, General and Administrative Expenses

The following table provides information regarding our selling, general and administrative (SG&A) expenses during the periods indicated (dollars in thousands):

Three Months EndedSeptember 30,ChangeNine Months EndedSeptember 30,Change20252024AmountPercent20252024AmountPercentSelling and marketing $77,058 $54,329 $22,729 42%$205,466 $172,700 $32,766 19%General and administrative 102,620 15,424 87,196 565%157,707 69,473 88,234 127%Total $179,678 $69,753 $109,925 158%$363,173 $242,173 $121,000 50%

Selling and marketing expenses were $77.1 million and $54.3 million for the three months ended September 30, 2025 and 2024, respectively. Selling and marketing expenses were $205.5 million and $172.7 million for the nine months ended September 30, 2025 and 2024, respectively. The increases in both periods were primarily due to higher professional and consulting expenses, higher employee-related expenses, higher marketing expense related to ONAPGO, which was launched in second quarter of 2025, and the Company's share of commercial expenses from the collaboration arrangement with Biogen. 

General and administrative expenses were $102.6 million and $15.4 million for the three months ended September 30, 2025 and 2024